Cookson, T. A., Stern, N. C., Sutton, R. T., Fedorak, R., Halloran, B., Dieleman, L. A., . . . Kroeker, K. (2019). A142 INFLAMMATORY BOWEL DISEASE PATIENTS REQUIRE AN INCREASED ADALIMUMAB DRUG LEVEL TO SIMULTANEOUSLY ACHIEVE CLINICAL AND BIOLOGICAL REMISSION. J Can Assoc Gastroenterol.
Chicago Style CitationCookson, T A., et al. "A142 INFLAMMATORY BOWEL DISEASE PATIENTS REQUIRE AN INCREASED ADALIMUMAB DRUG LEVEL TO SIMULTANEOUSLY ACHIEVE CLINICAL AND BIOLOGICAL REMISSION." J Can Assoc Gastroenterol 2019.
MLA CitationCookson, T A., et al. "A142 INFLAMMATORY BOWEL DISEASE PATIENTS REQUIRE AN INCREASED ADALIMUMAB DRUG LEVEL TO SIMULTANEOUSLY ACHIEVE CLINICAL AND BIOLOGICAL REMISSION." J Can Assoc Gastroenterol 2019.
Warning: These citations may not always be 100% accurate.